Possible Bearish Signals With ResMed Insiders Disposing Stock
Possible Bearish Signals With ResMed Insiders Disposing Stock
Many ResMed Inc. (NYSE:RMD) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When analyzing insider transactions, it is usually more valuable to know whether insiders are buying versus knowing if they are selling, as the latter sends an ambiguous message. However, if numerous insiders are selling, shareholders should investigate more.
在過去一年中，許多瑞思邁公司（NYSE:RMD）的內部人士拋售了他們的股票，這可能會引起公司股東的興趣。分析內部交易時，通常更有價值的是了解內部人員是買入還是賣出，而不是知道他們是賣出還是買入，後者會傳遞出模棱兩可的信息。然而，如果多名內部人士正在出售股票，股東應該進行更多調查。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
雖然我們永遠不會建議投資者僅基於公司董事已經做出的決策而做出決策，但同時我們認爲完全忽略內部交易是愚蠢的。
ResMed Insider Transactions Over The Last Year
過去一年中的瑞思邁內部交易
In the last twelve months, the biggest single sale by an insider was when the Founder, Peter Farrell, sold US$5.0m worth of shares at a price of US$237 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$212. So it is hard to draw any strong conclusion from it.
在過去的十二個月中，創始人彼得·法雷爾賣出了總價值500萬美元的股票，每股價格爲237美元。我們通常不喜歡看到內部人士賣出股票，但是銷售價格越低，我們就越擔心。這次銷售價格遠高於當前股價212美元，因此很難從中得出任何明顯結論。
ResMed insiders didn't buy any shares over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
過去一年中，瑞思邁內部人士沒有購買任何股票。您可以在下面的圖表中查看過去一年中公司和個人的內部交易。單擊下面的圖表，您可以查看每個內部交易的詳細信息！
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
對於那些喜歡發現潛力股票的人，可以免費查看最新內部交易股票的小盤公司名單，這可能正是您要找的機會。
ResMed Insiders Are Selling The Stock
瑞思邁內部人士正在拋售股票
The last three months saw significant insider selling at ResMed. Specifically, Independent Director Karen Drexler ditched US$91k worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.
過去三個月中，瑞思邁的內部人士大量拋售股票。具體而言，獨立董事Karen Drexler在這段時間內拋售了價值91,000美元的股票，我們沒有記錄任何購買。總的來說，這使我們有些謹慎，但這不是全部。
Does ResMed Boast High Insider Ownership?
瑞思邁是否擁有高度內部持股？
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. We usually like to see fairly high levels of insider ownership. ResMed insiders own 0.8% of the company, currently worth about US$258m based on the recent share price. I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
觀察一個公司的總內部持股水平可以幫助您了解它們是否與普通股東保持良好的一致性。我們通常喜歡看到相當高的內部持股水平。瑞思邁內部人士擁有該公司的0.8%股份，根據最近的股價計算，價值約2.58億美元。我喜歡看到這種股權內部持股水平，因爲它提高了管理層考慮股東最佳利益的機會。
What Might The Insider Transactions At ResMed Tell Us?
瑞思邁的內部交易可能會告訴我們什麼？
An insider sold ResMed shares recently, but they didn't buy any. And even if we look at the last year, we didn't see any purchases. On the plus side, ResMed makes money, and is growing profits. While insiders do own a lot of shares in the company (which is good), our analysis of their transactions doesn't make us feel confident about the company. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for ResMed.
一名內部人士最近出售了瑞思邁的股票，但他們沒有進行任何買入。即使我們查看過去一年，也沒有看到任何購買記錄。好的一面是，瑞思邁在賺錢，並且利潤在增長。雖然內部人士擁有大量公司股份（這是好事），但我們對他們的交易分析並不讓我們對該公司感到自信。因此，您一定要查看此免費報告，顯示瑞思邁的分析師預測。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然，您可能會在其他地方找到一項出色的投資。因此，請查看此免費的有趣公司列表。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
對於本文而言，內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置，但不包括衍生交易或間接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者，發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論，只使用公正的方法論，我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議，也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意，我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有反饋？關於內容有所顧慮？直接和我們聯繫。或者發送電子郵件至editorial-team@simplywallst.com。
譯文內容由第三人軟體翻譯。